Trial · NCT07895355
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ORR as assessed by the Investigator per RECIST v1.1 | From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months | |
| Primary | The incidence and severity of AEs, vital signs, physical examinations, ECGs, and laboratory test | Screening through 120 days after the last dose of RC148/telisotuzumab adizutecan/bevacizumab or 28 days after the last dose of 5-FU/LV, whichever is late | |
| Secondary | RC148 and Telisotuzumab adizutecan concentrations at each time-point post-dosing | 24 months | |
| Secondary | Maximum concentration (Cmax) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Time to Cmax (Tmax) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Area under the concentration-time curve for a dosing interval (AUCtau) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Area under the concentration-time curve extrapolated to infinity (AUCinf) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Elimination half-life (t1/2) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Incidence of ADA for RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Onset timing of ADA for RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Duration of ADA for RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Titers of ADA for RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Incidence of NAb for RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | PFS as assessed by the Investigator per RECIST v1.1 | From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months | |
| Secondary | TTR as assessed by the Investigator per RECIST v1.1 | From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months | |
| Secondary | DCR as assessed by the Investigator per RECIST v1.1 | From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months | |
| Secondary | DoR as assessed by the Investigator per RECIST v1.1 | From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months | |
| Secondary | OS as assessed by the Investigator per RECIST v1.1 | From randomization date until lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07895355/registered